Evidence map›Paper›PMID 22905253›Full record

ArticlePloS one2012

Identifying the genetic variation of gene expression using gene sets: application of novel gene Set eQTL approach to PharmGKB and KEGG.

Ryan Abo, Gregory D Jenkins, Liewei Wang, Brooke L Fridley

Abstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Integrative gene set analysis: application to platinum pharmacogenomics.Omics : a journal of integrative biology · 2014
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ryan AboDivision of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, United States of America.
Gregory D Jenkins
Liewei Wang
Brooke L Fridley

Funding

Tissue CoreP50CA102701 · NCI · MAYO CLINIC ROCHESTER · PI COHEN, PETER A · 2004 to 2018
$32.7M
Pharmacogenetics of Phase II Drug Metabolizing EnzymesU19GM061388 · NIGMS · MAYO CLINIC ROCHESTER · PI WANG, LIEWEI, WEINSHILBOUM, RICHARD M. · 2010 to 2014
$15.8M
PHARMACOGENETICS OF PHASE II DRUG METABOLIZING ENZYMESU01GM061388 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2000 to 2009
$15.7M
Pharmacogenomics and Mechanisms of Cytidine AnaloguesR01CA138461 · NCI · MAYO CLINIC ROCHESTER · PI WANG, LIEWEI · 2009 to 2013
$1.5M
Role of Vav1 protooncogene in pancreatic cancerP20CA102701 · NCI · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI CHARI, SURESH T. · 2003 to 2003
$1.5M
Pharmacogenomics of a Cytidine Analogue, GemcitabineK22CA130828 · NCI · MAYO CLINIC ROCHESTER · PI WANG, LIEWEI · 2008 to 2010
$492k
Integrative genomic models for analysis of pharmacogenomic studiesR21CA140879 · NCI · MAYO CLINIC ROCHESTER · PI FRIDLEY, BROOKE L · 2009 to 2010
$299k
Bayesian hierarchical nonlinear models for pharmacogenomic cytotoxicity studiesR21GM086689 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI FRIDLEY, BROOKE L · 2011 to 2012
$232k
NCI NIH HHS CA102701NCI NIH HHS CA130828NCI NIH HHS CA138461NCI NIH HHS CA140879NCI NIH HHS K22 CA130828NCI NIH HHS P20 CA102701NCI NIH HHS P50 CA102701NCI NIH HHS R01 CA138461NCI NIH HHS R21 CA140879NIGMS NIH HHS GM61388NIGMS NIH HHS GM86689NIGMS NIH HHS R21 GM086689NIGMS NIH HHS U01 GM061388NIGMS NIH HHS U19 GM061388
6 · The paper itself

Abstract

Genetic variation underlying the regulation of mRNA gene expression in humans may provide key insights into the molecular mechanisms of human traits and complex diseases. Current statistical methods to map genetic variation associated with mRNA gene expression have typically applied standard linkage and/or association methods; however, when genome-wide SNP and mRNA expression data are available performing all pair wise comparisons is computationally burdensome and may not provide optimal power to detect associations. Consideration of different approaches to account for the high dimensionality and multiple testing issues may provide increased efficiency and statistical power. Here we present a novel approach to model and test the association between genetic variation and mRNA gene expression levels in the context of gene sets (GSs) and pathways, referred to as gene set - expression quantitative trait loci analysis (GS-eQTL). The method uses GSs to initially group SNPs and mRNA expression, followed by the application of principal components analysis (PCA) to collapse the variation and reduce the dimensionality within the GSs. We applied GS-eQTL to assess the association between SNP and mRNA expression level data collected from a cell-based model system using PharmGKB and KEGG defined GSs. We observed a large number of significant GS-eQTL associations, in which the most significant associations arose between genetic variation and mRNA expression from the same GS. However, a number of associations involving genetic variation and mRNA expression from different GSs were also identified. Our proposed GS-eQTL method effectively addresses the multiple testing limitations in eQTL studies and provides biological context for SNP-expression associations.

Indexed as

Gene Expression RegulationGenetic VariationCell LineChromosome MappingComputational BiologyDatabases, GeneticGene Expression ProfilingGenome-Wide Association StudyGenotypeHumansPhenotypePolymorphism, Single NucleotidePrincipal Component AnalysisQuantitative Trait LociSoftware

Identifiers

PMID22905253
PMCPMC3419168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.